Status:
TERMINATED
Topical FK506 (Tacrolimus) for Prevention of Immune Reactions Following Penetrating Keratoplasty
Lead Sponsor:
University Hospital Freiburg
Collaborating Sponsors:
Sucampo Pharmaceuticals, Inc.
Conditions:
Penetrating Keratoplasty
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Background: Patients following allogeneic keratoplasty are treated with topical and frequently with systemic steroids to prevent immune reactions. Steroids are known to yield good results, but exert a...
Eligibility Criteria
Inclusion
- Penetrating keratoplasty for Keratoconus
- Penetrating keratoplasty for Fuchs endothelial dystrophie
- Penetrating keratoplasty for Bullous keratopathy
Exclusion
- Glaucoma
- Limbal stem cell deficiency
- Herpetic eye disease
- Repeat Keratoplasty
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00463723
Last Update
April 20 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.